Following up on their identification of a core oncogenic program in SS that included CDK4, Jerby-Arnon et al. found that CDK4/6 inhibitors acted synergistically with histone deacetylase (HDAC) inhibitors in SS [22]. Here, CDK4 is linked to synovial sarcoma.